Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Virological Methods

• Publication date

  2000-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0166-0934(99)00163-9PMID 10716348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Distinct Biological Properties of Human and Serological

  2004cited by this paper
• Analysis of the Critical Domain in the V3 Loop of Human Immunodeficiency Virus Type 1 gp120 Involved in CCR5 Utilization

  1999cited by this paper
• HIV treatment failure: testing for HIV resistance in clinical practice.

  1998cited by this paper
• A new classification for HIV-1

  1998cited by this paper
• Patterns of CCR5, CXCR4, and CCR3 Usage by Envelope Glycoproteins from Human Immunodeficiency Virus Type 1 Primary Isolates

  1998cited by this paper
• Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients

  1998cited by this paper
• Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral Research.

  1998cited by this paper
• Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

  1998cited by this paper
• In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression

  1997cited by this paper
• A new reporter cell line to monitor HIV infection and drug susceptibility in vitro.

  1997cited by this paper
• Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection

  1997cited by this paper
• Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals

  1997cited by this paper
• Human immunodeficiency virus type 1 protease inhibitors.

  1997cited by this paper
• Additional mutations detected in sequential HIV‐1 isolates from ZDV‐treated patients

  1997cited by this paper
• HIV entry and tropism: the chemokine receptor connection.

  1997cited by this paper
• A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates.

  1997cited by this paper
• HIV entry and tropism: the chemokine receptor connection.

  1997cited by this paper
• CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef

  1996cited by this paper
• A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

  1996cited by this paper
• Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

  1996cited by this paper
• Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages

  1996cited by this paper
• Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

  1996cited by this paper
• HIV-1 subtype and second-receptor use

  1996cited by this paper
• Clinical significance of drug resistance in HIV‐1 infection

  1996cited by this paper
• Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)

  1996cited by this paper
• CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.

  1996cited by this paper
• Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure.

  1996cited by this paper
• CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1

  1996cited by this paper
• Identification of a major co-receptor for primary isolates of HIV-1

  1996cited by this paper
• HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

  1996cited by this paper
• Rational approaches to resistance: nucleoside analogues.

  1996cited by this paper
• HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

  1996cited by this paper
• Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients

  1996cited by this paper
• In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

  1995cited by this paper
• Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy

  1995cited by this paper
• Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.

  1995cited by this paper
• Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy

  1995cited by this paper
• Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

  1994cited by this paper
• A Sensitive Reporter Cell Line for HIV-1 tat Activity, HIV-1 Inhibitors, and T Cell Activation Effects

  1994cited by this paper
• Identification of HIV1 determinants for T lymphoid cell line infection.

  1993cited by this paper
• Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group

  1993cited by this paper
• Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.

  1993cited by this paper
• Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.

  1993cited by this paper
• HIV‐1 biological phenotype in long‐term infected individuals evaluated with an MT‐2 cocultivation assay

  1992cited by this paper
• An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1

  1992cited by this paper
• Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo

  1992cited by this paper
• Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories

  1992cited by this paper
• Characterization of HIV Isolates Arising After Prolonged Zidovudine Therapy

  1992cited by this paper
• Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene

  1992cited by this paper
• Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

  1991cited by this paper
• Synergism and antagonism in chemotherapy

  1991cited by this paper
• Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.

  1991cited by this paper
• Variations in growth capacity of HIV in peripheral blood mononuclear cell preparations from different individuals.

  1990cited by this paper
• Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay

  1990cited by this paper
• Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity

  1988cited by this paper
• The role of mononuclear phagocytes in HTLV-III/LAV infection.

  1986cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• CD4-Based Chimeric Antigen Receptor (CAR)-T Cells With Resistance to HIV-1 Infection and Enhanced Anti-HIV Efficacy: Covalent Interaction Between CD4-CAR and HIV-1 Envelope Glycoprotein.

  2026cites this paper
• Extracellular Microvesicles Released From Brain Endothelial Cells are Detected in Animal Models Of HIV-1 Signifying Unresolved Inflammation

  2021cites this paper
• Regulatory T Cells Contribute to HIV-1 Reservoir Persistence in CD4+ T Cells Through Cyclic Adenosine Monophosphate–Dependent Mechanisms in Humanized Mice In Vivo

  2017cites this paper
• Review: Comprehensive review on treatment of HIV.

  2016cites this paper
• Comprehensive review on treatment of HIV.

  2016influential citation
• Visualizing the Behavior of HIV-Infected T Cells In Vivo Using Multiphoton Intravital Microscopy.

  2016cites this paper
• Identification of novel cellular components associated with HIV-1 early nucleoprotein complexes

  2012cites this paper
• HIV-infected T cells are migratory vehicles for viral dissemination

  2012cites this paper
• HIV-1 envelope-induced signaling mediates actin cytoskeleton rearrangements necessary for fusion and entry

  2009cites this paper
• Mutation of critical serine residues in HIV-1 matrix result in an envelope incorporation defect which can be rescued by truncation of the gp41 cytoplasmic tail.

  2009cites this paper
• In vivo biotinylation and capture of HIV-1 matrix and integrase proteins.

  2009cites this paper
• Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assay.

  2007cites this paper
• CCR5 signaling through phospholipase D involves p44/42 MAP‐kinases and promotes HIV‐1 LTR‐directed gene expression

  2007cites this paper
• Characterization of replication defects induced by mutations in the basic domain and C-terminus of HIV-1 matrix.

  2007cites this paper
• Conserved amino acids of the human immunodeficiency virus type 2 Vpx nuclear localization signal are critical for nuclear targeting of the viral preintegration complex in non-dividing cells.

  2006cites this paper
• Genotypic and phenotypic variation in the human immunodeficiency viruses

  2005cites this paper
• A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors.

  2005cites this paper
• Role of Neutralizing Antibodies in Protective Immunity Against HIV

  2005cites this paper
• Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors.

  2005cites this paper
• High-Throughput Human Immunodeficiency Virus Type 1 (HIV-1) Full Replication Assay That Includes HIV-1 Vif as an Antiviral Target

  2005cites this paper
• Role of Human Immunodeficiency Virus Type 1 Matrix Phosphorylation in an Early Postentry Step of Virus Replication

  2004cites this paper
• Adenovirus Expressing a Bioluminescence Reporter Gene and cMAGI cell Assay for the Detection of HIV-1

  2004cites this paper
• Substitution of HIV Type 1 Nef with HTLV-1 p12

  2004cites this paper
• Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors.

  2003cites this paper
• Blockade of Human Immunodeficiency Virus Type 1 Expression by Caveolin-1

  2002cites this paper
• Technologies for measuring HIV-1 drug resistance

  2002cites this paper
• Evaluation of drug resistance in HIV infection.

  2002cites this paper
• Role of lipid rafts in virus assembly and budding.

  2002cites this paper
• Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5).

  2001cites this paper
• The C-Terminal Proline-Rich Tail of Human Immunodeficiency Virus Type 2 Vpx Is Necessary for Nuclear Localization of the Viral Preintegration Complex in Nondividing Cells

  2000cites this paper